Literature DB >> 17539815

A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease.

Giovanni Tarantino1, Paolo Conca, Vincenzo Basile, Antonio Gentile, Domenico Capone, Giuliano Polichetti, Emilio Leo.   

Abstract

AIM: Liver damage due to facultative hepatotoxins is scarcely foreseeable. We evaluated the prevalence of acute drug-induced liver injury (DILI) in a specific setting, assessing eventual interactions with pre-existing hepatic illnesses.
METHODS: The research was carried out in an Italian tertiary care hospital, by analyzing 248 patients with non-advanced liver disease, divided into two well-matched groups: 174 patients (median age 53, 94 females) with hepatitis C virus-related chronic hepatitis; and 74 (median age 55, 39 females) with non-alcoholic fatty liver disease (NAFLD).
RESULTS: Six patients (2.4% of the whole population) belonging to the NAFLD group (chi(2)-test, P = 0.004) suffered from acute hepatoxicity related to the following drugs, that is antihypertensive, acting on platelet aggregation, antimicrobial, non-steroidal anti-inflammatory and proton pump inhibitor. The NAFLD presence was an independent risk factor in determining drug-related acute hepatitis, with an odds ratio of 3.95 (95% confidence intervals: 11.48-1.35). Central obesity was relevant in every patient with acute toxicity. Alcohol consumption and drug association did not influence the acute drug-induced liver damage.
CONCLUSION: NAFLD conveys a nearly fourfold increase of DILI risk in obese middle-aged patients. NAFLD, characterized by mitochondrial dysfunction, could predispose to drug-induced hepatotoxicity that probably shares the same pathophysiological mechanism.

Entities:  

Year:  2007        PMID: 17539815     DOI: 10.1111/j.1872-034X.2007.00072.x

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  42 in total

1.  Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update.

Authors:  Shiv Kumar Sarin; Ashok Choudhury; Manoj K Sharma; Rakhi Maiwall; Mamun Al Mahtab; Salimur Rahman; Sanjiv Saigal; Neeraj Saraf; A S Soin; Harshad Devarbhavi; Dong Joon Kim; R K Dhiman; Ajay Duseja; Sunil Taneja; C E Eapen; Ashish Goel; Q Ning; Tao Chen; Ke Ma; Z Duan; Chen Yu; Sombat Treeprasertsuk; S S Hamid; Amna S Butt; Wasim Jafri; Akash Shukla; Vivek Saraswat; Soek Siam Tan; Ajit Sood; Vandana Midha; Omesh Goyal; Hasmik Ghazinyan; Anil Arora; Jinhua Hu; Manoj Sahu; P N Rao; Guan H Lee; Seng G Lim; Laurentius A Lesmana; Cosmas Rinaldi Lesmana; Samir Shah; V G Mohan Prasad; Diana A Payawal; Zaigham Abbas; A Kadir Dokmeci; Jose D Sollano; Gian Carpio; Ananta Shresta; G K Lau; Md Fazal Karim; Gamal Shiha; Rino Gani; Kemal Fariz Kalista; Man-Fung Yuen; Seema Alam; Rajeev Khanna; Vikrant Sood; Bikrant Bihari Lal; Viniyendra Pamecha; Ankur Jindal; V Rajan; Vinod Arora; Osamu Yokosuka; Madunil A Niriella; Hai Li; Xiaolong Qi; Atsushi Tanaka; Satoshi Mochida; Dominic Ray Chaudhuri; Ed Gane; Khin Maung Win; Wei Ting Chen; Mohd Rela; Dharmesh Kapoor; Amit Rastogi; Pratibha Kale; Archana Rastogi; Chhagan Bihari Sharma; Meenu Bajpai; Virender Singh; Madhumita Premkumar; Sudhir Maharashi; A Olithselvan; Cyriac Abby Philips; Anshu Srivastava; Surender K Yachha; Zeeshan Ahmad Wani; B R Thapa; Anoop Saraya; Ashish Kumar; Manav Wadhawan; Subash Gupta; Kaushal Madan; Puja Sakhuja; Vivek Vij; Barjesh C Sharma; Hitendra Garg; Vishal Garg; Chetan Kalal; Lovkesh Anand; Tanmay Vyas; Rajan P Mathur; Guresh Kumar; Priyanka Jain; Samba Siva Rao Pasupuleti; Yogesh K Chawla; Abhijit Chowdhury; Shahinul Alam; Do Seon Song; Jin Mo Yang; Eileen L Yoon
Journal:  Hepatol Int       Date:  2019-06-06       Impact factor: 6.047

2.  Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines.

Authors:  Harshad Devarbhavi; Guruprasad Aithal; Sombat Treeprasertsuk; Hajime Takikawa; Yimin Mao; Saggere M Shasthry; Saeed Hamid; Soek Siam Tan; Cyriac Abby Philips; Jacob George; Wasim Jafri; Shiv K Sarin
Journal:  Hepatol Int       Date:  2021-02-27       Impact factor: 6.047

3.  The effect of tert-butyl hydroperoxide-induced oxidative stress on lean and steatotic rat hepatocytes in vitro.

Authors:  Otto Kučera; René Endlicher; Tomáš Roušar; Halka Lotková; Tomáš Garnol; Zdeněk Drahota; Zuzana Cervinková
Journal:  Oxid Med Cell Longev       Date:  2014-03-31       Impact factor: 6.543

Review 4.  Drug metabolism alterations in nonalcoholic fatty liver disease.

Authors:  Matthew D Merrell; Nathan J Cherrington
Journal:  Drug Metab Rev       Date:  2011-05-25       Impact factor: 4.518

Review 5.  Risk factors for idiosyncratic drug-induced liver injury.

Authors:  Naga Chalasani; Einar Björnsson
Journal:  Gastroenterology       Date:  2010-04-12       Impact factor: 22.682

Review 6.  Practical guidelines for diagnosis and early management of drug-induced liver injury.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

Review 7.  Molecular mechanisms involved in NAFLD progression.

Authors:  Mariano Malaguarnera; Michelino Di Rosa; Ferdinando Nicoletti; Lucia Malaguarnera
Journal:  J Mol Med (Berl)       Date:  2009-04-08       Impact factor: 4.599

8.  A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen.

Authors:  Anaïs Michaut; Dounia Le Guillou; Caroline Moreau; Simon Bucher; Mitchell R McGill; Sophie Martinais; Thomas Gicquel; Isabelle Morel; Marie-Anne Robin; Hartmut Jaeschke; Bernard Fromenty
Journal:  Toxicol Appl Pharmacol       Date:  2015-12-29       Impact factor: 4.219

Review 9.  Drug-induced liver injury: is it somehow foreseeable?

Authors:  Giovanni Tarantino; Matteo Nicola Dario Di Minno; Domenico Capone
Journal:  World J Gastroenterol       Date:  2009-06-21       Impact factor: 5.742

Review 10.  Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics.

Authors:  David E Amacher; Shelli J Schomaker; Jiri Aubrecht
Journal:  Mol Diagn Ther       Date:  2013-12       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.